Pharmaceutical & Medical Device Risk-Sharing & Value-Based Pricing and Reimbursement Schemes

23-24 April 2009, Brussels, Belgium.
There is clearly an increasing need for more innovative pricing and reimbursement agreements to help to balance the (often) conflicting objectives of pharmaceutical and medical technology manufacturers, payers, health technology assessors (HTA), physicians and patients.

There is a sustained increase in the cost of healthcare and ever-increasing range of expensive drugs and technologies available as potential therapies. Clearly, difficult choices need to be made by HTAs about which products receive funding from increasingly restricted healthcare budgets, especially with often insufficient clinical and real-life evidence available.

In terms of innovative agreements, risk-sharing and value-based schemes (for example) are being proposed more often by more manufacturers, in more countries. Such agreements are increasingly being seen as a method in which pharma and medical device companies can obtain HTA approval to finance the drug from limited budgets, but also a strategy to gain a competitive advantage and preferential market access.

Both life sciences companies and policy-makers are looking to achieve a clearer picture of how risk-sharing and value-based agreements can and do work effectively in the real-world. Many complex agreements exist in various countries, whilst some governments and pharma companies in other markets may alternatively have less experience with such schemes.

Many stakeholders need answers to important questions such as: "What is the definition of risk-sharing and value-based pricing schemes? Are such schemes necessary? What are the alternatives? What successful models exist? How can clear endpoints and goals be defined? How can we measure performance effectively? And how different schemes are being viewed by different stakeholders? Can risk-sharing and value-based agreements bring a competitive advantage to pharma companies?"

Why Attend?

  • Benchmark, network and co-operate with policy makers and key, influential figures. Get the best and most focused picture of risk-sharing and value-based pricing models today.
  • Understand what are the most up to date, innovative agreement solutions and future trends in different countries globally.
  • Find out if risk-sharing and value-based pricing schemes can help pharma and medical device manufacturers achieve preferential market access and a competitive advantage.
  • Learn how drug effectiveness, value and safety is being demonstrated in different regions, in real-life.
  • Understand the best ways to communicate value with stakeholders and achieve maximum patient and market access.
  • Hear the perspectives of all stakeholder groups: Ministries of Health, HTA Agencies, Insurers, Doctors, Patients and patient groups, Health economists and the Pharmaceutical Industry.
  • Discover how payers are evaluating a range of complex pricing and reimbursement agreements.
  • Understand what patients want and what they define as a quality treatment, that enhances their lives.

Who Should Attend?
Pharmaceutical companies, Vice-Presidents, Directors, Managers involved in:
Pricing & Reimbursement, Health Economics & Outcomes, Government & Stakeholder Relations, Regulatory Affairs, Medical Affairs, Marketing, Therapy Area Heads, Market Access, Country Managers

Solution providers consultants:
CEOs, Business Development, Senior Consultants, Regional Heads

Independent Academics, Health Economists, Senior Doctors, & Patient Representatives.

For further information and registration, please visit:
http://www.nextlevelpharma.com/events/view/22

About NextLevel Pharma
NextLevel Pharma is a leading, global strategic business information and opportunity provider for the international life sciences industry.

NextLevel Pharma brings the life sciences industry closer together and organise intelligent conferences and events for industry, personalised meetings for individual companies, as well as tailored partnering services.

For more information, please visit www.nextlevelpharma.com.

Most Popular Now

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...